Tiziana Plans Phase 2 Antibody Study in Moderate to Severe Covid-19

 

• Since the anti-inflammatory effect of the nasally administered Foralumab is through the modulation of the immune system and not by directly targeting Covid-19, this therapeutic approach could be useful for newly identified Covid-19 variants in the UK, South Africa and Brazil.
• Foralumab is the first monoclonal antibody that can be dosed nasally or orally, due to its ability to effect systemic immunity via the epithelial lining of the nose, respiratory tract and gut.
• The direct rapid delivery of Foralumab to the nasal passage and respiratory tract was shown in a previous study of mild to moderate Covid-19 patients to suppress lung inflammation, as evident from CT scans and reduced systemic markers of inflammation including interleukin-6 and C-reactive protein.

https://www.biospace.com/article/releases/tiziana-plans-phase-2-clinical-study-in-moderate-to-severe-covid-19-patients-with-nasal-administration-of-foralumab-a-fully-human-anti-cd3-monoclonal-antibody/